In summary, our systematic review and meta-analysis demonstrated the potential of radiomics in predicting treatment outcomes and responses in patients with NSCLC receiving targeted therapies such as EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.